Copyright
©2010 Baishideng.
World J Gastroenterol. Aug 7, 2010; 16(29): 3616-3629
Published online Aug 7, 2010. doi: 10.3748/wjg.v16.i29.3616
Published online Aug 7, 2010. doi: 10.3748/wjg.v16.i29.3616
No. | Autoantibody | Autoantigen properties | Prevalence in PBC (%) | Clinical associations | Ref. |
ANA | |||||
1 | Anti-chromatin | Chromatin | 8.9-25.0 | Anti-chromatin antibodies are reported to be associated with disease activity in AIH, but their roles in PBC remains to be investigated | [99,127-129] |
2 | Anti-dsDNA | Double-stranded deoxyribonucleic acid | 17.0-22.0 | Anti-dsDNA antibodies are one of important criteria for the diagnosis of SLE. Co-existence of AMA and anti-dsDNA autoantibodies can be considered the serological profile of AIH/PBC overlap syndrome | [76,127,128,130,131] |
3 | Anti-ssDNA | Single-stranded deoxyribonucleic acid | 59.0-71.0 | Anti-ssDNA antibodies can be detected in many diseases | [132,133] |
4 | Anti-histone | Histone | 43.6 | Anti-histone antibodies are generally considered to be related to drug-induced lupus, though it can be detected in many autoimmune diseases including PBC | [132,134] |
5 | Anti-scl-70 | Topoisomerase-1 | 3.0-24.0 | Anti-scl-70 antibody serve as a specific maker for diffuse SSc and presents in 30%-60% of subjects with diffuse SSc | [127,132] |
6 | Anti-Sm | Proteins of 28/29, 16, 16.5, 18, and 12, 11, 6 kDa which participate in pre-messenger RNA processing into spliced mature mRNA | 7.0-34.0 | Anti-Sm autoantibodies are highly specific for SLE | [76,127,132,135] |
7 | Anti-SSA | Intracellular ribonucleoproteins of 60 and 52 kDa that are associated with small RNAs | 5.0-30.0 | Anti-Ro(SS-A) and anti-La(SS-B) antibodies are more frequently seen in SS and SLE. Their presence in PBC suggests that PBC often overlaps with SS | [76,127,132,135,136] |
8 | Anti-SSB | An intracellular ribonucleoprotein of 47 kDa that are associated with small RNAs | 2.0-21.0 | ||
9 | Anti-RNP | Ribonucleoprotein | 5.0 | More frequently seen in SLE | [76,127] |
10 | Anti-Jo-1 | Histidyl tRNA synthetase | 26.0 | Anti-Jo-1 antibodies are predominantly detected in patients with myositis | [135] |
11 | Anti-U1RNP | U1snRNPs that contain specific proteins of 70, 33 and 20 kDa | 3.1-5.0 | Anti-U1snRNP antibodies predominantly present in SLE, and can be detected in PBC patients. The clinical significance of anti-U1snRNP antibodies in PBC is unknown | [137,138] |
Other liver diseases-associated autoantibodies | |||||
12 | Anti-SMA | A variety of target antigens including F-actin, G-actin, myosin, tropomyosin, troponin, desmin, vimentin, keratin, etc. | 8.0-25.0 | Anti-SMAs present mainly in AIH-I, and can also be detected in chronic active hepatitis. The presences of anti-SMAs in PBC are potential indicators of AIH/PBC overlap syndrome | [131,139] |
13 | Anti-SLA | SLA and liver and pancreas antigen | 2.0-3.9 | Anti-SLAs are autoantibodies seen in AIH-III.The presences of SLA autoantibodies in PBC indicate secondary autoimmune hepatitis | [9,140,141] |
14 | Anti-LKM | Liver kidney microsomal antigen | 0.7 | Anti-LKM antibodies occur preferentially in AIH-II. Anti-LKM autoantibodies can be seen in 21.4% of HCV-infected PBC patients, which suggests a close association between LKM and HCV-infected PBC | [142] |
15 | Anti-ASGPR | Asialoglycoprotein receptor | 22.0-23.0 | Anti-ASGPR antibodies mainly present in AIH and PBC. The autoimmune responses against ASGPR have been implicated in the development of AIH and PBC | [143-146] |
16 | Anti-LCM | Liver cell membrane specific antigen | 42.0 | Anti-LCM antibodies are detected predominantly in patients with HBsAg-negative chronic active hepatitis, but are also found in other liver diseases such as PBC | [147-149] |
17 | Anti-LSP | Liver specific protein | 48.5 | Anti-LSP antibodies present in viral hepatitis and autoimmune liver disease, and are found to correlate with severity of periportal inflammation and piecemeal necrosis in PBC | [144,150] |
18 | Anti-calreticulin | Calreticulin | 20.0 | Anti-calreticulin antibodies present in autoimmune liver disorder and IBD. They are not specific for PBC | [151,152] |
19 | Anti-FH | Fumarate hydratase | 19.4 | Anti-FH antibodies are found to be present predominantly in AIH. It can also be detected in PBC and other liver disease. The prevalence and clinic significance of anti-FH in PBC need further study | [153] |
20 | Anti-PGAM-B | Phosphoglycerate mutase isozyme B | 16.7 | Anti-PGAM-B antibodies are found to be present in 70.0% of AIH and 16.7% of PBC. It is also present in about 10% of viral hepatitis and 3.7% of healthy control. The clinical significance of anti-FH needs further study | [154] |
21 | Anti-p97/VCP | P97/valosin-containing protein | 12.5 | Anti-p97/VCP antibodies predominantly present in PBC, and can be detected in about 9.7% of AIH. The presence of anti-p97/VCP antibodies in PBC suggests less progressive disease course and benign prognosis | [155-157] |
22 | Anti-GSTA1-1 | Glutathione S-transferase | 10.0 | Anti-GST autoantibodies are detected in 16.0% of AIH and 10.0% of PBC. Patients of AIH with positive anti-GST have severe diseases and poor prognosis | [158] |
23 | Anti-ASL | Argininosuccinate lyase | 23.0 | Anti-argininosuccinate lyase is a newly identified autoantibody in liver disease and its clinical relevance remains unknown | [159] |
24 | Anti-calmodulin | Calmodulin | IgM 50.0 | Anti-calmodulin autoantibodies neither associate with anti-SMA, ANA and AMA, nor with hyperglobulinemia. The clinic significant of anti-calmodulin is unclear | [160] |
IgA 42.9 | |||||
Gastroenteropathy-associated autoantibodies | |||||
25 | ASCA | Baker's yeast saccharomyces cerevisiae | 24.2 | ASCA serves as a serological marker of Crohn’s disease, and has also been detected in other autoimmune disorders and in 5%-6.3% of blood donors. The prevalence of ASCA in AIH is 20%-30%, in AMA-negative PBC 44%. ASCA is common in PBC patients and correlates with higher level of circulating IgA. The prevalence of ASCA in PBC may be an indirect sign of enhanced mucosal immunity, but does not necessarily indicate concomitant inflammatory bowel disease | [161-163] |
26 | Anti-Galectin-3 | Galectin-3, a member of -galactoside-binding lectins | 30.0 | Anti-Galectin-3 autoantibodies are primarily associated with Crohn's disease, and correlate negatively with disease activity. The significance of anti-Galectin-3 IgG autoantibodies in patients with PBC is unknown | [164] |
27 | Anti-tTG | Tissue transglutaminase | 10.0-26.7 | Anti-tTG autoantibody is mainly found in celiac disease. The prevalence of anti-tTG in PBC varies due to different types of substrate utilized in detection | [127,165,166] |
28 | AGA | Gliadin | 16.0-21.0 | Anti-gliadin antibodies are considered as the most reliable serological markers for celiac disease. They are also frequently seen in PBC, and IgA subclass of anti-gliadin antibodies are more pronounced in patients with Scheuer's stage III-IV disease | [166,167] |
Vasculitis-associated autoantibodies | |||||
29 | ANCA | Antigens including proteinase 3, myeloperoxidase, bactericidal/permeability-increasing protein, lactoferrin,human leukocyte elastase, cathepsin G, lysozyme, azurocidin, etc. | 2-26 | ANCAs are primarily associated with systemic vasculitides such as Wegener’s granulomatosis, microscopic polyangiitis and Churg-Strauss syndrome | [76,131,168] |
30 | Anti-MPO | Myeloperoxidase | 9.0 | Predominantly in microscopic polyangiitis, necrotizing and crescentic glomerulonephritis, Churg-Strauss syndrome | [169] |
31 | Anti-PR3 | Proteinase 3 | 3.0 | Predominantly in Wegener’s granulomatosis, and also detectable in microscopic polyangiitis, necrotizing and crescentic glomerulonephritis | [127] |
32 | Anti-LF | Lactoferrin | 25.0-35.7 | Are detected in several autoimmune disorders, such as Crohn's disease, SLE, systemic vasculitides. They are not specific markers for PBC | [170,171] |
Thrombophilia-associated autoantibodies | |||||
33 | Anti-β2GPI | β(2)-glycoprotein I | IgG 2-15 | Represent specific features of patients with antiphospholipid syndrome. Their presence in PBC often indicates severe disease and worse prognosis | [127,172,173] |
34 | Acl | Cardiolipin | IgG 27.3 | ||
35 | Anti-PS | Phosphatidylserine | IgM 75 | ||
36 | Anti-PT | Prothrombin | IgG 7 | ||
37 | Anti-PE | Phosphatydilethanolamine | IgG 5 | ||
Diabetes mellitus-associated autoantibodies | |||||
38 | Anti-GAD | Glutamic acid decarboxylase | 5.5 | Anti-GAD occurs preferentially in the patients with type 1 diabetes. Clinical significance of Anti-GAD in PBC is unclear | [174] |
39 | Anti-SOX13 | Transcriptional factor SOX13 | 18.0 | SOX13 was initially identified in type 1 diabetes. The present of anti-SOX13 in PBC may merely indicate an immune response to products of damage to parenchymal tissue | [175] |
Autoimmune thyroid diseases-associated autoantibodies | |||||
40 | Anti-TG | Thyroglobulin | 54.5 | Anti-TG, anti-TPO and anti-TR are markers of autoimmune thyroid diseases. Their significances in PBC are unknown | [176] |
41 | Anti-TPO | Thyroid peroxidase | 45.5 | ||
42 | Anti-TR | TSH receptor | 9.1 | ||
Others autoantibodies | |||||
43 | Anti-CCP | Cyclic citrullinated peptide | 2.7-4.0 | Anti-CCP antibodies are highly specific for RA with sensitivity of 60%-70%. Presence of anti-CCP antibodies in PBC patients suggests RA overlap | [125,126,177] |
44 | Anti-ClpP | Microbial caseinolytic proteases P | 30-47 | ClpP is highly conserved among bacteria. Anti-ClpP in PBC suggests infection factors and molecular mimicry involved in the pathogenesis | [178,179] |
45 | Anti-β-subunit of bacterial RNA polymerase | β-subunit of bacterial RNA-polymerase | 32.8 | These autoantibodies in PBC, suggest bacterial triggers of PBC | [180] |
46 | Anti-EPO | Eosinophil peroxidase | 52.5 | PBC patients with positive anti-EPO antibodies have less peripheral eosinophils | [181] |
47 | Anti-p53 | Nuclear protein of 53 kDa that regulates cell proliferation and apoptosis | 8.0 | Anti-p53 autoantibodies are commonly seen in malignancies and organ-specific autoimmune diseases such as type 1 diabetes, thyroid diseases, PBC and AIH | [182] |
48 | Anti-acetylcholine receptor | Nicotinic acetylcholine receptor | 58.8-74.0 | Anti-acetylcholine receptor antibodies are primarily associated with myasthenia gravis, though PBC patients with positive anti-acetylcholine receptor antibodies do not have clinical symptoms of myasthenia | [169,183,184] |
49 | Anti-CAII | Carbonic anhydrase II | 18-31 | Anti-CAII antibody is likely a nonspecific marker of autoimmunity. It has been detected in a variety of autoimmune diseases, including Graves’ disease, type 1 diabetes, SS, SLE, AIH and PBC. In cases of PBC, no significant correlation has been found between anti-CAII antibody and AMA | [185-189] |
50 | Anti-α enolase | α-enolase | 28.6 | Anti-α-enolase antibodies present in a variety of inflammatory and autoimmune disorders, such as SLE, IBD, RA and AIH, and are not likely to be specific markers for any disease. They might be involved in destruction of biliary epithelium and are associated with hepatic failure | [190-195] |
51 | Anti-HSP | Heat shock proteins | 45.7 | Enhanced biliary expression of heat shock protein is found in PBC. Anti-HSPs are common in PBC, and are related to titers of AMA. They might cross-react with the main mitochondrial antigens in PBC | [196-199] |
52 | Anti-FKBP12 | FK506 binding protein 12 | 44.4 | The significance of anti-FKBP12 antibodies in PBC is unclear | [200] |
- Citation: Hu CJ, Zhang FC, Li YZ, Zhang X. Primary biliary cirrhosis: What do autoantibodies tell us? World J Gastroenterol 2010; 16(29): 3616-3629
- URL: https://www.wjgnet.com/1007-9327/full/v16/i29/3616.htm
- DOI: https://dx.doi.org/10.3748/wjg.v16.i29.3616